1
|
Reddy N, Lynch B, Gujral J, Karnik K. Regulatory landscape of alternatives to animal testing in food safety evaluations with a focus on the western world. Regul Toxicol Pharmacol 2023; 143:105470. [PMID: 37591329 DOI: 10.1016/j.yrtph.2023.105470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 08/09/2023] [Accepted: 08/11/2023] [Indexed: 08/19/2023]
Abstract
Traditional animal models are increasingly being replaced by new approach methodologies (NAMs) which focus on predicting toxicity of chemicals based on mechanistic data rather than apical endpoint data usually obtained from animal models. Beyond in vitro genetic tests, however, only a handful of NAMs have been successfully implemented in regulatory decision-making processes, mostly in the cosmetics and chemicals sector. Regulatory guidance on food safety testing in many jurisdictions still relies on data obtained from animal studies. This is due to the lack of validated models to predict systemic toxicity, which is essential to develop health-based guidance values for food additives. Other factors limiting the adoption of NAMs into food safety assessment include sector legislation lagging behind scientific progress, and lack of training and expertise to use the new models. While regulatory and industry bodies are working to combat these challenges, more needs to be done before these models can be used as standalone tools for regulatory decision-making. This review summarizes the current state and challenges of regulatory acceptance of NAMs for decision-making, and the efforts by governing bodies and industry to transition from animal testing for food safety assessments.
Collapse
Affiliation(s)
- Navya Reddy
- Intertek Health Sciences Inc., 2233 Argentia Rd., Suite 201, Mississauga, ON, L5N 2X7, Canada
| | - Barry Lynch
- Intertek Health Sciences Inc., 2233 Argentia Rd., Suite 201, Mississauga, ON, L5N 2X7, Canada.
| | - Jaspreet Gujral
- Tate & Lyle, 5450 Prairie Stone Pkwy, Hoffman Estates, IL, 60192, USA
| | - Kavita Karnik
- Tate & Lyle PLC, 5 Marble Arch, London, W1H 7EJ, United Kingdom
| |
Collapse
|
2
|
Cayley AN, Foster RS, Hill E, Kane S, Kocks G, Myden A, Newman D, Stalford SA, Vessey JD, Zarei R, De Oliveira AAF. Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment. ALTEX 2022; 40:34–52. [PMID: 35575642 DOI: 10.14573/altex.2201311] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 05/02/2022] [Indexed: 01/20/2023]
Abstract
The traditional paradigm for safety assessment of chemicals for their carcinogenic potential to humans relies heavily on a battery of well-established genotoxicity tests, usually followed up by long-term, high-dose rodent studies. There are a variety of problems with this approach, not least that the rodent may not always be the best model to predict toxicity in humans. Consequently, new approach methodologies (NAMs) are being developed to replace or enhance predictions coming from the existing assays. However, a combination of the data arising from NAMs is likely to be required to improve upon the current paradigm, and consequently a framework is needed to combine evidence in a meaningful way. Adverse outcome pathways (AOPs) represent an ideal construct on which to organize this evidence. In this work, a data structure outlined previously was used to capture AOPs and evidence relating to carcinogenicity. Knowledge held within the predictive system Derek Nexus was extracted, built upon, and arranged into a coherent network containing 37 AOPs. 60 assays and 351 in silico alerts were then associated with KEs in this network, and it was brought to life by associating data and contextualizing evidence and predictions for over 13,400 compounds. Initial investigations into using the network to view knowledge and reason between evidence in different ways were made. Organizing knowledge and evidence in this way provides a flexible framework on which to carry out more consistent and meaningful carcinogenicity safety assessments in many different contexts.
Collapse
Affiliation(s)
| | | | - Emma Hill
- Lhasa Limited, Leeds, West Yorkshire, UK
| | | | | | - Alun Myden
- Lhasa Limited, Leeds, West Yorkshire, UK
| | | | | | | | - Reza Zarei
- Lhasa Limited, Leeds, West Yorkshire, UK
| | | |
Collapse
|
3
|
Ambe K, Suzuki M, Ashikaga T, Tohkin M. Development of quantitative model of a local lymph node assay for evaluating skin sensitization potency applying machine learning CatBoost. Regul Toxicol Pharmacol 2021; 125:105019. [PMID: 34311055 DOI: 10.1016/j.yrtph.2021.105019] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 06/13/2021] [Accepted: 07/21/2021] [Indexed: 11/21/2022]
Abstract
The estimated concentrations for a stimulation index of 3 (EC3) in murine local lymph node assay (LLNA) is an important quantitative value for determining the strength of skin sensitization to chemicals, including cosmetic ingredients. However, animal testing bans on cosmetics in Europe necessitate the development of alternative testing methods to LLNA. A machine learning-based prediction method can predict complex toxicity risks from multiple variables. Therefore, we developed an LLNA EC3 regression model using CatBoost, a new gradient boosting decision tree, based on the reliable Cosmetics Europe database which included data for 119 substances. We found that a model using in chemico/in vitro tests, physical properties, and chemical information associated with key events of skin sensitization adverse outcome pathway as variables showed the best performance with a coefficient of determination (R2) of 0.75. In addition, this model can indicate the variable importance as the interpretation of the model, and the most important variable was associated with the human cell line activation test that evaluate dendritic cell activation. The good performance and interpretability of our LLNA EC3 predictable regression model suggests that it could serve as a useful approach for quantitative assessment of skin sensitization.
Collapse
|
4
|
Sachana M, Willett C, Pistollato F, Bal-Price A. The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays. Reprod Toxicol 2021; 103:159-170. [PMID: 34147625 PMCID: PMC8279093 DOI: 10.1016/j.reprotox.2021.06.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 05/19/2021] [Accepted: 06/04/2021] [Indexed: 12/24/2022]
Abstract
Current in vivo DNT testing for regulatory purposes is not effective. In vitro assays anchored to key neurodevelopmental processes are available. Development of Adverse Outcome Pathways is required to increase mechanistic understanding of DNT effects. DNT Integrated Approaches to Testing and Assessment for various regulatory purposes should be developed. The OECD Guidance Document on use of in vitro DNT battery of assays is currently under development.
A major challenge in regulatory developmental neurotoxicity (DNT) assessment is lack of toxicological information for many compounds. Therefore, the Test Guidelines programme of the Organisation for Economic Cooperation and Development (OECD) took the initiative to coordinate an international collaboration between diverse stakeholders to consider integration of alternative approaches towards improving the current chemical DNT testing. During the past few years, a series of workshops was organized during which a consensus was reached that incorporation of a DNT testing battery that relies on in vitro assays anchored to key neurodevelopmental processes should be developed. These key developmental processes include neural progenitor cell proliferation, neuronal and oligodendrocyte differentiation, neural cell migration, neurite outgrowth, synaptogenesis and neuronal network formation, as well key events identified in the existing Adverse Outcome Pathways (AOPs). AOPs deliver mechanistic information on the causal links between molecular initiating event, intermediate key events and an adverse outcome of regulatory concern, providing the biological context to facilitate development of Integrated Approaches to Testing and Assessment (IATA) for various regulatory purposes. Developing IATA case studies, using mechanistic information derived from AOPs, is expected to increase scientific confidence for the use of in vitro methods within an IATA, thereby facilitating regulatory uptake. This manuscript summarizes the current state of international efforts to enhance DNT testing by using an in vitro battery of assays focusing on the role of AOPs in informing the development of IATA for different regulatory purposes, aiming to deliver an OECD guidance document on use of in vitro DNT battery of assays that include in vitro data interpretation.
Collapse
Affiliation(s)
- Magdalini Sachana
- Environment Health and Safety Division, Environment Directorate, Organisation for Economic Co-Operation and Development (OECD), 75775, Paris Cedex 16, France
| | - Catherine Willett
- Humane Society International, 1255 23rd Street NW, Washington, DC, 20037, USA
| | | | - Anna Bal-Price
- European Commission Joint Research Centre (JRC), Ispra, Italy.
| |
Collapse
|
5
|
Nakagawa S, Okamoto M, Yoshihara K, Nukada Y, Morita O. Grouping of chemicals based on the potential mechanisms of hepatotoxicity of naphthalene and structurally similar chemicals using in vitro testing for read-across and its validation. Regul Toxicol Pharmacol 2021; 121:104874. [PMID: 33493583 DOI: 10.1016/j.yrtph.2021.104874] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 12/25/2020] [Accepted: 01/19/2021] [Indexed: 11/21/2022]
Abstract
Integrated Approaches to Testing and Assessment provides a framework to improve the reliability of read-across for chemical risk assessment of systemic toxicity without animal testing. However, the availability of only a few case studies hinders the use of this concept for regulatory purposes. Thus, we compared the biological similarity of structurally similar chemicals using in vitro testing to demonstrate the validity of this concept for grouping chemicals and to extract key considerations in read-across. We analyzed the hepatotoxicity of naphthalene and three chemicals structurally similar to naphthalene (2,7-naphthalenediol, 1,5-naphthalenediol, and 1-naphthol) for which 90-day repeated dose toxicity data are available. To elucidate and compare their potential mechanisms, we conducted in vitro microarray analysis using rat primary hepatocytes and validated the results using a biomarker and metabolic activation analysis. We observed that 2,7-naphthalenediol, 1,5-naphthalenediol, and 1-naphthol had similar potential mechanisms, namely, induction of oxidative stress by their metabolic activation. Conversely, naphthalene did not show a similar toxicity effect. The existing in vivo data confirmed our grouping of chemicals based on this potential mechanism. Thus, our findings suggest that in vitro toxicogenomics and related biochemical assays are useful for comparing biological similarities and grouping chemicals based on their toxicodynamics for read-across.
Collapse
Affiliation(s)
- Shota Nakagawa
- Kao Corporation, Safety Science Research, 2606, Akabane, Ichikai-Machi, Haga-Gun, Tochigi, 321-3497, Japan.
| | - Maiko Okamoto
- Kao Corporation, Safety Science Research, 2606, Akabane, Ichikai-Machi, Haga-Gun, Tochigi, 321-3497, Japan
| | - Keita Yoshihara
- Kao Corporation, Safety Science Research, 2606, Akabane, Ichikai-Machi, Haga-Gun, Tochigi, 321-3497, Japan
| | - Yuko Nukada
- Kao Corporation, Safety Science Research, 2606, Akabane, Ichikai-Machi, Haga-Gun, Tochigi, 321-3497, Japan
| | - Osamu Morita
- Kao Corporation, Safety Science Research, 2606, Akabane, Ichikai-Machi, Haga-Gun, Tochigi, 321-3497, Japan
| |
Collapse
|
6
|
Jacobs MN, Colacci A, Corvi R, Vaccari M, Aguila MC, Corvaro M, Delrue N, Desaulniers D, Ertych N, Jacobs A, Luijten M, Madia F, Nishikawa A, Ogawa K, Ohmori K, Paparella M, Sharma AK, Vasseur P. Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens. Arch Toxicol 2020; 94:2899-2923. [PMID: 32594184 PMCID: PMC7395040 DOI: 10.1007/s00204-020-02784-5] [Citation(s) in RCA: 59] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 05/07/2020] [Indexed: 12/26/2022]
Abstract
While regulatory requirements for carcinogenicity testing of chemicals vary according to product sector and regulatory jurisdiction, the standard approach starts with a battery of genotoxicity tests (which include mutagenicity assays). If any of the in vivo genotoxicity tests are positive, a lifetime rodent cancer bioassay may be requested, but under most chemical regulations (except plant protection, biocides, pharmaceuticals), this is rare. The decision to conduct further testing based on genotoxicity test outcomes creates a regulatory gap for the identification of non-genotoxic carcinogens (NGTxC). With the objective of addressing this gap, in 2016, the Organization of Economic Cooperation and Development (OECD) established an expert group to develop an integrated approach to the testing and assessment (IATA) of NGTxC. Through that work, a definition of NGTxC in a regulatory context was agreed. Using the adverse outcome pathway (AOP) concept, various cancer models were developed, and overarching mechanisms and modes of action were identified. After further refining and structuring with respect to the common hallmarks of cancer and knowing that NGTxC act through a large variety of specific mechanisms, with cell proliferation commonly being a unifying element, it became evident that a panel of tests covering multiple biological traits will be needed to populate the IATA. Consequently, in addition to literature and database investigation, the OECD opened a call for relevant assays in 2018 to receive suggestions. Here, we report on the definition of NGTxC, on the development of the overarching NGTxC IATA, and on the development of ranking parameters to evaluate the assays. Ultimately the intent is to select the best scoring assays for integration in an NGTxC IATA to better identify carcinogens and reduce public health hazards.
Collapse
Affiliation(s)
- Miriam N Jacobs
- Centre for Radiation, Chemical and Environmental Hazards (CRCE), Public Health England, Chilton, UK.
| | - Annamaria Colacci
- Center for Environment, Prevention and Health, Regional Agency for Prevention, Environment and Energy Emilia Romagna Region (Arpae), Bologna, Italy
| | - Raffaella Corvi
- European Commission Joint Research Centre (EC JRC), Ispra, Italy
| | - Monica Vaccari
- Center for Environment, Prevention and Health, Regional Agency for Prevention, Environment and Energy Emilia Romagna Region (Arpae), Bologna, Italy
| | | | | | - Nathalie Delrue
- Organisation for Economic Cooperation and Development (OECD), Paris, France
| | | | - Norman Ertych
- German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessment, Diedersdorfer Weg 1, 12277, Berlin, Germany
| | - Abigail Jacobs
- US Food and Drug Administration (FDA), Silver Spring, MD, USA
| | - Mirjam Luijten
- National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | - Federica Madia
- European Commission Joint Research Centre (EC JRC), Ispra, Italy
| | | | - Kumiko Ogawa
- National Institute of Health Sciences, Kawasaki, Japan
| | - Kiyomi Ohmori
- Kanagawa Prefectural Institute of Public Health, Chigasaki, Japan
| | - Martin Paparella
- Division of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
| | | | | |
Collapse
|
7
|
Basketter D, Azam P, Casati S, Corvaro M, Ezendam J, Griem P, Hubesch B, Irizar A, Kern P, Manou I, Mehling A, Rossi LH. Applying non-animal strategies for assessing skin sensitisation report from an EPAA/cefic-LRI/IFRA Europe cross sector workshop, ECHA helsinki, February 7th and 8th 2019. Regul Toxicol Pharmacol 2019; 109:104477. [PMID: 31586681 DOI: 10.1016/j.yrtph.2019.104477] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 09/06/2019] [Accepted: 09/13/2019] [Indexed: 11/22/2022]
Abstract
Four years on since the last cross sector workshop, experience of the practical application and interpretation of several non-animal assays that contribute to the predictive identification of skin sensitisers has begun to accumulate. Non-animal methods used for hazard assessments increasingly are contributing to the potency sub-categorisation for regulatory purposes. However, workshop participants generally supported the view that there remained a pressing need to build confidence in how information from multiple methods can be combined for classification, sub-categorisation and potency assessment. Furthermore, the practical experience gained over the last few years, highlighted the overall high potential value of using the newly validated methods and testing strategies, but also that limitations for certain substance/product classes may become evident with further use as had been the case with other new regulatory methods. As the available information increases, review of the data and collated experience could further determine strengths and limitations leading to more confidence in their use. Finally, the need for a substantial and universally accepted dataset of non-sensitisers and substances of different sensitising potencies, based on combined human and in vivo animal data for validation of methods and test strategies was re-emphasised.
Collapse
|